5 recent updates in peripheral intervention

In the field of interventional cardiology, there has been an increased interest in trends in peripheral intervention.

Cardiology Today’s Intervention has compiled a list of five recent advances in peripheral intervention in 2018.

STOP-IC: Cilostazol safe, effective in endovascular treatment

Cilostazol treatment is safe and effective in patients with femoropopliteal disease undergoing endovascular treatment, according to results published in the Journal of Endovascular Therapy.

“Several studies have reported favorable primary patency after endovascular therapy using self-expanding nitinol stents for femoropopliteal occlusive disease compared with balloon angioplasty,” Yoshimitsu Soga, MD, PhD, from the department of cardiology at Kokura Memorial Hospital in Kitakyushu, Japan, and colleagues wrote in the study background. “In recent years, advances in devices and improved therapeutic outcomes have expanded the applicability of [endovascular therapy] to more patients. However, post-[endovascular therapy] restenosis remains a major limitation.”

RANGER SFA provides more evidence on paclitaxel-coated balloons for femoropopliteal treatment

At 1 year, use of a paclitaxel-coated balloon in the femoropopliteal segment resulted in greater rates of patency and fewer interventions compared with use of conventional balloon angioplasty.

However, researchers observed similar symptomatic, hemodynamic and health-related quality-of-life improvements with the drug-coated balloon (Ranger, Boston Scientific) and conventional balloon angioplasty.

SCAI launches new toolkit for PAD diagnosis, treatment

SAN DIEGO — The Society for Cardiovascular Angiography and Interventions announced at its annual meeting the launch of the SCAI PAD Diagnosis and Treatment Resource Center, an ongoing, patient-centered quality improvement initiative focused on raising awareness of peripheral artery disease in the cardiology and internal medicine communities.

The new toolkit provides information on the underlying risks of PAD, which is estimated to impact more than 10 million patients in the United States, but is plagued by underdiagnosis a lack of screening and undertreatment.

Peripheral DCB now approved for treatment of long lesions

Medtronic announced the FDA approved its drug-coated balloon for treatment of patients with long superficial femoral artery lesions up to 360 mm.

According to a press release from the company, the approval of the new indication for the DCB (IN.PACT Admiral) was based on the results of the IN.PACT Global study, which found that in a subset of 227 patients with mean lesion length of 28.7 cm, 1-year patency was 89.1% and 1-year clinically driven target lesion revascularization was 7.1%.

DCBs help prevent edge stenosis after stent grafting in SFA occlusions

The use of a drug-coated balloon after stent graft treatment of superficial femoral artery occlusive disease reduced risk for edge stenosis, decreased target lesion revascularization and improved primary patency, researchers reported.

The researchers analyzed 110 patients (mean age, 73 years; 78 men) with long superficial femoral artery (SFA) occlusions who were treated with a covered stent graft (Viabahn, W.L. Gore and Associates) between October 2011 and July 2016. Among the cohort, 34.5% had reinforcement with a DCB at the distal edge of the stent graft.